Ultragenyx Pharmaceutical Inc. (RARE) Statistics & Valuation Metrics - Stocknear

Ultragenyx Pharmaceutical...

NASDAQ: RARE · Real-Time Price · USD
31.82
0.54 (1.73%)
At close: Sep 05, 2025, 3:59 PM
31.82
0.00%
After-hours: Sep 05, 2025, 05:10 PM EDT

Ultragenyx Pharmaceutical Statistics

Share Statistics

Ultragenyx Pharmaceutical has 96.37M shares outstanding. The number of shares has increased by 2.58% in one year.

96.37M
2.58%
2.21%
90.48%
89.64M
71,382
3.63%

Short Selling Information

The latest short interest is 8.41M, so 8.72% of the outstanding shares have been sold short.

8.41M
8.72%
9.03%
4.85

Valuation Ratios

The PE ratio is -6.69 and the forward PE ratio is -8.67. Ultragenyx Pharmaceutical's PEG ratio is 0.28.

-6.69
-8.67
6.8
3.7
14.92
-9.03
0.28
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Ultragenyx Pharmaceutical.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 2.37, with a Debt / Equity ratio of 3.56.

2.37
2.24
3.56
-1.94
-2.16
-8.5

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
$432.94K
$-439.86K
1,294
0.37
1.7

Taxes

1.6M
-0.28%

Stock Price Statistics

The stock price has increased by -44.59% in the last 52 weeks. The beta is 0.24, so Ultragenyx Pharmaceutical's price volatility has been higher than the market average.

0.24
-44.59%
30.61
37.92
59.01
1,965,948

Income Statement

In the last 12 months, Ultragenyx Pharmaceutical had revenue of 560.23M and earned -569.18M in profits. Earnings per share was -6.29.

560.23M
483.5M
-535.97M
-569.18M
-469M
-504.55M
-6.29
Full Income Statement

Balance Sheet

The company has 173.73M in cash and 910.01M in debt, giving a net cash position of -736.28M.

173.73M
910.01M
-736.28M
-3.96B
1.31B
426.54M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -414.19M and capital expenditures -7.49M, giving a free cash flow of -421.68M.

-414.19M
-7.49M
-421.68M
-4.66
Full Cash Flow Statement

Margins

Gross margin is 86.3%, with operating and profit margins of -95.67% and -101.6%.

86.3%
-95.67%
-101.31%
-101.6%
-83.72%
-95.67%
-75.27%

Dividends & Yields

RARE does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for RARE is $75, which is 139.8% higher than the current price. The consensus rating is "Buy".

$75
139.8%
Buy
12
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

-3.36
4